A New Biomarker Panel in Bronchoalveolar Lavage for an Improved Lung Cancer Diagnosis

Uribarri, María; Hormaeche, Itsaso; Zalacaín, Rafael; López-Vivanco, G.; Martinez, Antonio; Nagore, Daniel; Ruiz-Argüello, M. Begoña

doi:10.1097/jto.0000000000000282

Cited by 37 publications

(32 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Second, DNA methylation test is cheaper than microarray, with microarray not being routinely used owing to the high cost. Third, since the bronchoalveolar-washing specimen is a useful sample for lung cancer biomarker identification (35), the DNA methylation assay does not require brushing.…”

Section: Discussionmentioning

confidence: 99%

PCDHGA12 methylation biomarker in bronchial washing specimens as an adjunctive diagnostic tool to bronchoscopy in lung cancer

et al. 2018

View full text Add to dashboard Cite

The use of bronchoscopy is central to the diagnosis of lung cancer. However, the sensitivity of bronchoscopy is low. In addition, bronchial washing cytology, which is a routine adjunctive test, does not significantly improve the performance of bronchoscopy owing to its low sensitivity. To enhance the diagnostic performance of bronchoscopy, the protocadherin GA12 () methylation biomarker in bronchial washings was introduced as a novel adjunctive diagnostic test. A total of 98 patients who underwent bronchoscopy owing to suspicion of lung cancer were analyzed. Cytological examination and methylation biomarker testing of the bronchial washing fluid were performed. The performance of the tests was analyzed. The final diagnosis in 60 patients was lung cancer and in 38 patients was benign disease. The methylation biomarker had a sensitivity of 75.0%, a specificity of 78.9% and a positive predictive value (PPV) of 84.9%, whereas cytological assessment had a sensitivity of 45.0%, a specificity of 92.1% and a PPV of 90%. Patients with positive methylation test had an odds ratio for lung cancer of 11.25 (confidence interval, 4.25-29.8) compared with negative subjects. The combination of the two tests exhibited an increased sensitivity (83.3%), a specificity of 71.1% and a PPV of 82.0%. Furthermore, considering the non-diagnostic bronchoscopy group alone, the test demonstrated a sensitivity of 61.9% and a specificity of 78.9%. The results of the present study demonstrated that methylation, as a lung cancer biomarker in bronchial washings, may be a used as an adjunctive test to bronchoscopy.

show abstract

Section: Discussionmentioning

confidence: 99%

PCDHGA12 methylation biomarker in bronchial washing specimens as an adjunctive diagnostic tool to bronchoscopy in lung cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Such biomarkers have been sought as a means of facilitating LUSC diagnosis and monitoring, since their detection is easier than a more invasive biopsy procedure and allow rapid screening. Minimally invasive tumor biomarkers that are readily accessible in biofluids such as plasma, urine and bronchoalveolar lavage fluid (BALF) would thus offer a means of easily and effectively differentiating between patients with cancer and those with benign disease (4)(5)(6). Urine markers can be detected without exposing individuals to any risk, and urine is highly amenable to large-scale screening efforts.…”

Section: Introductionmentioning

confidence: 99%

“…However, the current biomarkers for the diagnosis of LUSC are mainly blood tumor markers such as squamous cell carcinoma (SCC) antigen and cytokeratin 19 fragment 21-1, but their sensitivity and specificity are low. There arw few studies on biomarkers of LUSC in easily accessible specimens, such as urine and BALF (4,5).…”

Section: Introductionmentioning

confidence: 99%

Evaluation of kininogen 1, osteopontin and α‑1‑antitrypsin in plasma, bronchoalveolar lavage fluid and urine for lung squamous cell carcinoma diagnosis

Wang

Zhang

2020

Oncol Lett

View full text Add to dashboard Cite

Lung squamous cell carcinoma (LUSC) progression is accompanied by changes in protein levels that may be reflected in body fluids, such as plasma, bronchoalveolar lavage fluid (BALF) and urine. Certain proteins present in these biofluids can facilitate lung cancer diagnosis. Kininogen 1 (KNG1), osteopontin (OPN) and α-1-antitrypsin (AAT) are associated with tumorigenesis. The present study aimed to explore the combined monitoring of plasma, urine and BALF to gain insight into LUSC by monitoring the levels of the above three protein using ELISA. LUSC (n=31) and healthy controls with benign lung diseases (n=20) were enrolled in the study. KNG1 levels in plasma, BALF and urine were significantly higher in patients with LUSC patients than in controls (P<0.0001, P<0.0001 and P=0.0010, respectively). OPN was upregulated in the plasma and BALF of patients with LUSC relative to controls (P=0.0107 and P=0.0004, respectively), whereas its levels in the urine of healthy controls were significantly higher (P=0.0088). Patients with LUSC had higher AAT levels in plasma, BALF and urine compared with those of the controls (P=0.0022, P=0.0014 and P=0.0005, respectively). Receiver operating characteristic analysis showed an area under the curve (AUC) of 0.81 for KNG1 in plasma, 0.91 in BALF and 0.81 in urine. The AUC for OPN was 0.71 in plasma, 0.83 in BALF and 0.75 in urine. The AUC for AAT was 0.74 in plasma, 0.74 in BALF and 0.86 in urine. Immunohistochemical staining in 20 paired LUSC and adjacent normal tissues showed that KNG1, OPN and AAT levels were higher in LUSC tissues. Therefore, our results showed that KNG1, OPN and AAT in biofluids might be useful for the diagnosis of LUSC. These markers in urine and BALF may be better than in plasma for detecting LUSC.

show abstract

“…Some cancer-specific peptides can be captured and analyzed to ascertain tumor status in vivo , and identification of such peptides might facilitate the development of biomarkers for early detection of lung cancer. Peripheral biofluids, such as serum and bronchoalveolar lavage fluid (BALF) have been used to detect lung cancer [5]. Recently, urine has attracted increased attention as a biospecimen because it remains relatively stable due to minimal post-sampling proteolysis.…”

Section: Introductionmentioning

confidence: 99%

Identification of urine biomarkers associated with lung adenocarcinoma

Wang

Zhang

2017

Oncotarget

View full text Add to dashboard Cite

Lung adenocarcinoma (LAC) progression is accompanied by changes in protein levels that may be reflected in body fluids, such as urine. Urine collected from LAC patients (n=34) and healthy controls (n=36) was analyzed via matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) combined with weak cationic exchange magnetic beads. The results revealed 76 urinary polypeptides significantly different between LAC patients and normal controls (P<0.05). Twenty-two of these peptides were up-regulated and 54 were down-regulated. Thirteen peptides had average peak intensities >600. Twelve of these 13 peptides were successfully identified using nano-liquid chromatography-tandem MS. Receiver operating characteristic analyses identified seven peptides with superior LAC diagnostic performances. Immunohistochemical staining in 20 paired LAC and adjacent normal tissues showed that IGKC, AAT, SH3BGRL3, osteopontin and gelsolin levels were higher in LAC tissues than in adjacent tissuesand were closely associated with LAC. Urinary peptides assessments may thus provide a novel, noninvasive, repeatable method for detecting and monitoring LAC. New, low-cost detection methods and bioinformatics tools are therefore urgently needed for the analysis of low abundance proteins and peptides in body fluids.

show abstract

A New Biomarker Panel in Bronchoalveolar Lavage for an Improved Lung Cancer Diagnosis

Cited by 37 publications

References 39 publications

PCDHGA12 methylation biomarker in bronchial washing specimens as an adjunctive diagnostic tool to bronchoscopy in lung cancer

PCDHGA12 methylation biomarker in bronchial washing specimens as an adjunctive diagnostic tool to bronchoscopy in lung cancer

Evaluation of kininogen 1, osteopontin and α‑1‑antitrypsin in plasma, bronchoalveolar lavage fluid and urine for lung squamous cell carcinoma diagnosis

Identification of urine biomarkers associated with lung adenocarcinoma

Contact Info

Product

Resources

About